Dyne Therapeutics, Inc. (DYN)
16.56
-0.60
(-3.50%)
USD |
NASDAQ |
Nov 16, 14:20
Dyne Therapeutics Enterprise Value : 2.324B for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 2.324B |
| November 12, 2026 | 2.296B |
| November 11, 2026 | 2.480B |
| November 10, 2026 | 2.467B |
| November 09, 2026 | 2.598B |
| November 06, 2026 | 2.495B |
| November 05, 2026 | 2.362B |
| November 04, 2026 | 2.583B |
| November 03, 2026 | 2.491B |
| November 02, 2026 | 2.351B |
| October 30, 2026 | 2.236B |
| October 29, 2026 | 2.302B |
| October 28, 2026 | 2.291B |
| October 27, 2026 | 2.283B |
| October 26, 2026 | 2.055B |
| October 23, 2026 | 2.036B |
| October 22, 2026 | 2.064B |
| October 21, 2026 | 2.120B |
| October 20, 2026 | 2.158B |
| October 19, 2026 | 1.963B |
| October 16, 2026 | 1.779B |
| October 15, 2026 | 1.974B |
| October 14, 2026 | 1.927B |
| October 13, 2026 | 1.976B |
| October 12, 2026 | 2.100B |
| Date | Value |
|---|---|
| October 09, 2026 | 2.227B |
| October 08, 2026 | 2.176B |
| October 07, 2026 | 2.102B |
| October 06, 2026 | 1.995B |
| October 05, 2026 | 2.002B |
| October 02, 2026 | 1.957B |
| October 01, 2026 | 2.073B |
| September 30, 2026 | 2.128B |
| September 29, 2026 | 2.020B |
| September 28, 2026 | 2.042B |
| September 25, 2026 | 1.991B |
| September 24, 2026 | 2.070B |
| September 23, 2026 | 2.024B |
| September 22, 2026 | 2.174B |
| September 21, 2026 | 2.171B |
| September 18, 2026 | 2.170B |
| September 17, 2026 | 2.327B |
| September 16, 2026 | 2.202B |
| September 15, 2026 | 2.300B |
| September 14, 2026 | 2.403B |
| September 11, 2026 | 2.352B |
| September 10, 2026 | 2.387B |
| September 09, 2026 | 2.514B |
| September 08, 2026 | 2.700B |
| September 04, 2026 | 3.357B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 487.93M |
| Amgen, Inc. | 292.70B |
| Anika Therapeutics, Inc. | 160.67M |
| BioCryst Pharmaceuticals, Inc. | 2.402B |
| Imunon, Inc. | 6.805M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -193.55M |
| Total Expenses (Quarterly) | 193.55M |
| EPS Diluted (Quarterly) | -1.065 |
| Earnings Yield | -21.95% |
| Normalized Earnings Yield | -21.95 |